214 related articles for article (PubMed ID: 17823934)
1. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
Neslund-Dudas C; Bock CH; Monaghan K; Nock NL; Yang JJ; Rundle A; Tang D; Rybicki BA
Prostate; 2007 Nov; 67(15):1654-63. PubMed ID: 17823934
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
[TBL] [Abstract][Full Text] [Related]
5. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
Torkko KC; van Bokhoven A; Mai P; Beuten J; Balic I; Byers TE; Hokanson JE; Norris JM; Barón AE; Lucia MS; Thompson IM; Leach RJ
Clin Cancer Res; 2008 May; 14(10):3223-9. PubMed ID: 18483391
[TBL] [Abstract][Full Text] [Related]
6. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
[TBL] [Abstract][Full Text] [Related]
8. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
[TBL] [Abstract][Full Text] [Related]
9. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
Scariano JK; Treat E; Alba F; Nelson H; Ness SA; Smith AY
Prostate; 2008 Dec; 68(16):1798-805. PubMed ID: 18780294
[TBL] [Abstract][Full Text] [Related]
10. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
Söderström T; Wadelius M; Andersson SO; Johansson JE; Johansson S; Granath F; Rane A
Pharmacogenetics; 2002 Jun; 12(4):307-12. PubMed ID: 12042668
[TBL] [Abstract][Full Text] [Related]
11. GEN GEN: the genomic genetic analysis of androgen-metabolic genes and prostate cancer as a paradigm for the dissection of complex phenotypes.
Reichardt JK
Front Biosci; 1999 Jul; 4():D596-600. PubMed ID: 10417059
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk.
Devgan SA; Henderson BE; Yu MC; Shi CY; Pike MC; Ross RK; Reichardt JK
Prostate; 1997 Sep; 33(1):9-12. PubMed ID: 9294620
[TBL] [Abstract][Full Text] [Related]
13. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.
Makridakis NM; Ross RK; Pike MC; Crocitto LE; Kolonel LN; Pearce CL; Henderson BE; Reichardt JK
Lancet; 1999 Sep; 354(9183):975-8. PubMed ID: 10501358
[TBL] [Abstract][Full Text] [Related]
14. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
Choi SY; Kim HJ; Cheong HS; Myung SC
Korean J Urol; 2015 Jan; 56(1):19-30. PubMed ID: 25598933
[TBL] [Abstract][Full Text] [Related]
15. Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients.
Margiotti K; Sangiuolo F; De Luca A; Froio F; Pearce CL; Ricci-Barbini V; Micali F; Bonafe M; Franceschi C; Dallapiccola B; Novelli G; Reichardt JK
Dis Markers; 2000; 16(3-4):147-50. PubMed ID: 11381197
[TBL] [Abstract][Full Text] [Related]
16. Associations between the SRD5A2 gene V89L and TA repeat polymorphisms and breast cancer risk: a meta-analysis.
Zhang D; Li Q; Qu HC; Yu T; Liu YR
Genet Mol Res; 2015 Aug; 14(3):9004-12. PubMed ID: 26345832
[TBL] [Abstract][Full Text] [Related]
17. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
[TBL] [Abstract][Full Text] [Related]
18. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
[TBL] [Abstract][Full Text] [Related]
19. [V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
Tong M; Jin YY; Li G; Liu SM; Ji CD
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):990-3. PubMed ID: 21218640
[TBL] [Abstract][Full Text] [Related]
20. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
